Mission Statement
Elan Drug Technologies develops and manufactures innovative pharmaceutical products that deliver clinically meaningful benefits to patients, using its extensive experience and proprietary drug technologies in partnership with pharmaceutical companies.
Profile
Elan Drug Technologies (EDT) is the world’s leading drug delivery company and is a business unit of Elan (NYSE:ELN). As a fully integrated drug delivery business, we deliver clinically meaningful benefits to patients, by using our extensive experience and proprietary delivery technologies in partnership with pharmaceutical companies to develop new and innovative products.
For 40 years, we have been applying our skills and knowledge from concept development, right through to full scale manufacturing. We have been, and continue to be, the drug delivery provider of choice for a broad range of pharmaceutical companies, including many of the world’s largest pharmaceutical companies. We offer our clients unrivalled drug delivery expertise with a suite of commercially launched, proprietary, technology-driven solutions.
From NanoCrystal® technology for poorly water soluble compounds, to customised oral drug technologies, we have a strong track record of innovation and experience.
Technologies
Elan Drug Technologies has a unique platform of validated technologies to offer our clients - from Oral controlled release, delayed release, pulsatile release delivery systems as well as technology solutions for poorly water soluble compounds.
We have a complete range of capabilities from formulation development through to commercial scale manufacture in modern facilities. Our technologies are supported by robust patent estate of over 1,700 patents and pending applications.
NanoCrystal® Technology – now commercialised involves reducing the size of drug particles, typically to less than 2,000 nanometres. By reducing particle size, the drug’s exposed surface area is increased. The nanoparticles are then stabilised to maintain their reduced particle size. The result is a stable drug formulation that exhibits an increased dissolution rate. With four products launched and US$1.8B+ annual in-market sales, it is a proven Innovation for poorly water-soluble compounds. Patent Protected with over 1,000 patents/patent applications in U.S. and rest of the world, it has been optimised and simplified from over 15 years of development behind the technology, is applicable to all dosage forms and has been manufactured at commercial scale since 2001.
Our Oral Controlled Release (OCR) technologies has been incorporated and successfully commercialised into two dozen products worldwide. Our Oral Controlled Release Technology platform allows a range of release profiles and dosage forms to be engineered. Customised release profiles for oral dosage forms such as extended release, delayed release and pulsatile release have all been developed and commercialised.
Agreements
Acorda Therapeutics
EDT developed Fampridine-SR, using one of their proprietary Oral Controlled Release Technologies, the MXDAS® (MatriX Drug Absorption System) Technology for Acorda Therapeutics. The FDA announced in May 2009 that the U.S. Food and Drug Administration (FDA) have accepted the Fampridine-SR New Drug Application (NDA) for filing, assigning Priority Review and a Prescription Drug User Fee Act (PDUFA) date of October 22, 2009. The PDUFA date is the target date for the FDA to complete its review of the Fampridine-SR NDA.
Johnson & Johnson Pharmaceutical
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for paliperidone palmitate, an investigational, once-monthly atypical antipsychotic intramuscular injection, for the treatment of schizophrenia and the prevention of recurrence of the symptoms of schizophrenia. Paliperidone palmitate is a long-acting injectable ester of the active ingredient in INVEGA™1 which utilises Elan's NanoCrystal® Technology. Upon approval, paliperidone palmitate will be marketed in the U.S. by Janssen, L.P.
MAP and AstraZeneca
Agreement to apply Elan's proprietary NanoCrystal® technology to defined inhalation therapies. MAP has been collaborating with Elan to develop a nebulised form of budesonide for the treatment of asthma. This agreement covers nebulised delivery of budesonide and combinations of budesonide with beta agonists. Budesonide is an anti-inflammatory corticosteroid indicated for the maintenance treatment of asthma as well as prophylactic therapy for this condition. In all delivery forms, including nebulised delivery, budesonide sales exceeded US$1bn worldwide in 2004. Asthma affects approximately 17 million Americans, 5 million of whom are children. The nebulised portion of the asthma market is the fastest growing segment, largely due to the increasingly high diagnosis rates for asthma in the paediatric population. MAP subsequently signed an agreement with AstraZeneca to commercialise this product.
Roche
A broad license agreement with Roche around Elan's proprietary NanoCrystal® technology. The agreement will provide Roche with access to NanoCrystal® technology and the right to apply it to a number of proprietary drug candidates. Elan will receive development milestones and royalties on sales of any product incorporating the use of NanoCrystal® technology.
Entremed
A License Agreement in which EntreMed has been granted rights to utilize Elan's proprietary NanoCrystal Technology to develop the oncology product candidate, Panzem® NCD (2ME2 or 2-methoxyestradiol). Under the terms of the License Agreement, Elan is eligible to receive payments upon the achievement of certain clinical, manufacturing, and regulatory milestones. Additionally, Elan will receive royalty payments based on sales of Panzem® NCD.
Abbott
A License Agreement in which Abbott has been granted US rights, in a partnership with AstraZeneca Pharmaceuticals, LP, to utilise Elan's proprietary NanoCrystal Technology to develop and commercialise a single fixed-dose combination product containing the active pharmaceutical ingredients in Abbott's TriCor® 145 (fenofibrate) and AstraZeneca's Crestor® (rosuvastatin calcium) products. Under the terms of the License Agreement, Elan will receive payments upon the achievement of development, clinical, and regulatory milestones for such new combination product. Additionally, Elan will receive royalty payments based on US sales of the combination product, if successfully developed and commercialized.
Zogenix
A License Agreement under which Zogenix has been granted exclusive US rights from an affiliate of Elan Corporation, plc (NYSE: ELN) (Elan) to develop and commercialize a late stage, controlled-release opioid for the treatment of pain. The product, which incorporates Elan’s proprietary SODAS® Technology, has previously demonstrated in a Phase 2 clinical trial a clinically acceptable safety profile and a reduction in pain intensity for chronic moderate to severe osteoarthritis pain patients across multiple dosage strengths. Under the terms of the Agreement, Elan will receive from Zogenix an undisclosed upfront payment and future payments upon the achievement of clinical and regulatory milestones for the product. Additionally, Elan will receive royalty payments based on sales of the product upon commercialization. Zogenix will assume responsibility for the clinical development and commercialisation of the product in the United States, and Elan will manufacture the product for Zogenix.
Management Team
Shane Cooke - Executive Vice President and Head, Elan Drug Technologies
Mr. Cooke was appointed a Director of Elan in May 2005. He joined Elan as Executive Vice President and Chief Financial Officer in July 2001 and was additionally appointed Head of EDT in May 2007. Prior to joining Elan, Mr. Cooke was Chief Executive of Pembroke Capital Limited, an aviation leasing company, and prior to that held a number of senior positions in finance in the banking and aviation industries. Mr. Cooke is a chartered accountant and a graduate of University College Dublin, Ireland.
Peter Thornton - Senior Vice President, Head of Product, Technology and Business Development
Mr. Thornton joined Elan in July 2007. He was formerly President and Chief Operating Officer of Circ Pharma Limited, a specialty pharmaceutical product development company from 2006 to 2007, Senior Vice President and Chief Financial Officer of Antigenics Inc., a NASDAQ listed biotechnology company from 2004 to 2006, as well as Senior Vice President of business operations at Elan from 1994 to 2004. Prior to joining Elan in 1994, Mr. Thornton worked for seven years with the international accounting firm KPMG in Ireland and France. Mr. Thornton is a Non-Executive Director of publicly-held Merrion Pharmaceuticals plc and previously of Cydex Pharmaceuticals Inc and Antigenics Inc. Mr. Thornton is a chartered accountant and holds a bachelor of commerce degree from University College Cork, Ireland.
Sharon Hamm - Senior Vice President, Technical Operations
Dr. Hamm joined Elan in December 1992, as Vice President, Regulatory. Dr Hamm has held a number of management roles at Elan encompassing regulatory, clinical development, quality, compliance, project management, portfolio management, pharmacovigilence, and general management. Prior to joining Elan, Dr. Hamm spent 12 years in various leadership roles at Solvay Pharmaceuticals including regulatory, compliance, pharmacovigilence, and clinical development. Dr. Hamm holds Pharmacy and Doctor of Pharmacy degrees from Mercer University, School of Pharmacy.
James L. Botkin - Senior Vice President, Operations
Mr. Botkin was appointed Senior Vice President and Head of Operations in Elan in June 2007 and was formerly Vice President and General Manager of Elan’s operations in Gainesville from October 2001 to June 2007. Before joining Elan, Mr. Botkin was president of Sharp Corporation, a private pharmaceutical packaging company from January 1996 to June 2001, as well as Vice President, US Production Operations of Sandoz Pharmaceutical Corporation until December 1995. He has held various general management, operational and quality roles with Glaxo, Smith and Nephew, Beecham Laboratories, Astra Pharmaceutical Products and Mead Johnson. Mr Botkin has a BSc in Chemistry from Miami University as well as an MBA in finance and marketing from the Illinois Benedictine University.
Tom Riordan - Vice President, Legal Counsel
Mr. Riordan joined Elan as Vice President and Head of the EDT legal group at the beginning of 2004 and has almost twenty years experience in private practice and in industry. Prior to joining Elan, he worked as in-house legal counsel for a number of multi-national companies in Ireland. Before moving into industry, Mr. Riordan also worked in private practice for several years, first with a law firm specialising in EU law in Brussels and subsequently with a large Irish firm in Dublin. Mr. Riordan is a solicitor and a law graduate of National University of Ireland Galway and the Université Libre de Bruxelles.
Gary Liversidge - Chief Technology Officer
Dr Liversidge was appointed Chief Technology Officer in October 2008. For more than 20 years, Dr Liversidge has been at the forefront of developing the NanoCrystal® technology and related technologies, at EDT. Since Elan’s acquisition of the technology in 1998, Dr Liversidge has served in a number of critical scientific and managerial positions related to the strategic advancement of EDT’s technologies, products and relationships, most recently as Sr. Director, EDT Business Development.
Key Web Pages
General data
Start year - 1969
Number of employees - 750
Ticker symbol - ELN
Press Releases
Head Office in Ireland:
Monksland
Athlone
Co Westmeath
Ireland
+353 90 64 95000
+353 90 64 95807
| Contact Details: |
| 3000 Horizon Drive |
| King of Prussia |
| PA |
| 19406 |
| United States of America |
| Tel: | +1 610 313 7045 |
| Fax: | |
| Email: | edtbusdev@elan.com |
| WWW: | www.elandrugtechnologies.com/
|
|
Loading...
|
Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 979 times since April 2007, the link to the organisation's website has been followed 61 times
Recent Search Terms used to find this page: project technical operations injectable | Crestor NCD number | NCD elan | MXDAS Technology patent | Elan s Nanocrystal technology commercialization | Elan s Nanocrystal technology commercialization | Elan s Nanocrystal technology commercialization | Elan s Nanocrystal technology commercialization | zogenix stock symbol | large pharmaceutical companies in-licensed EDT s NanoCrystal technology | .
Search for more companies in King of Prussia
Search for more companies in PA
This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for
Elan Drug Technologies 
